A couple of things: 1. Timing: 1/7/19 Assay development....is on...

A couple of things:
1. Timing:
1/7/19 Assay development....is on track in terms of technical milestones and scheduled completion. Phase 3: Assay validation phase...completion expected by Q4 CY2019.
31/7/19 - ThePhase 3 assay validation phase toanalytically validate the multiplex BARD1assay is near completion.
I'm thinking Mid August.

2. Upon completion of the development of the RUO BARD1 kit, BARD1 plans to work with Luminex to develop a commercial diagnostic version on the industry standard Luminex platform.
31/7/19 - ."Upon Successful Completion.......plans to commence verificationtesting in Q4 CY2019"
This indicates to me they have no doubt rather than quantifying their statements.

I think there is no doubt it will be on Luminex.

Finally I think the Company is on a sooner rather than later path to get this happening. I think the new board won't tolerate delays and wishwashy announcements about progress
31/7/19 -" commenced recruitment ofadditional staff for the Geneva facility to underpin and accelerate our research projects"


Their strategy:
31.7.19 "strategy seeks to commercialise its proprietary biomarkerplatform with a focus on advancing its BARD1 autoantibody tests"
"to build a leading Australian cancer diagnostics company"
"expand its cancer diagnostics portfolio through acquisition of complementary diagnostic assetsto deliver lifesaving diagnostic solutions."

All looks good to me but also looks like they might buy "diagnostic assets" which means we have to pay for what and how (Will $7m cover it? )?

R